Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Equity Bottom-Up

<ul>
<li>The owner and operator of Wildwood and dim t restaurants updates on trading for the first four and a half months to 17 May 2026 at its AGM.</li>
<li>Revenue has continued to increase on a like-for-like basis.</li>
<li>Served by the investment in improving the Wildwood estate as the four refurbished restaurants are showing significant revenue growth. </li>
</ul>


The owner and operator of Wildwood and dim t restaurants updates on trading for the first four and a half months to 17 May 2026 at its AGM.
Revenue has continued to increase on a like-for-like basis.
Served by the investment in improving the Wildwood estate as the four refurbished restaurants are showing significant revenue growth. 


<ul>
<li>The UK and European based manufacturer of the proprietary Neptune melt-blown material and specialist in the design, manufacture, and supply of acoustic and thermal insulation solutions announces its unaudited interim results for the six months ended 30 September.</li>
<li>Revenue in H1 2026 decreased by 12.3% to £8.59m (H1 2025: £9.79m), while the gross profit decreased by 4.6% to £2.90m (H1 2025: £3.04m). Cash was £0.09m from £1.68m in H1 2025 while group cash headroom was £1.52m.</li>
<li>The Group has focussed on winning new business in the UK and Germany, alongside cost control and efficiency improvements. </li>
</ul>


The UK and European based manufacturer of the proprietary Neptune melt-blown material and specialist in the design, manufacture, and supply of acoustic and thermal insulation solutions announces its unaudited interim results for the six months ended 30 September.
Revenue in H1 2026 decreased by 12.3% to £8.59m (H1 2025: £9.79m), while the gross profit decreased by 4.6% to £2.90m (H1 2025: £3.04m). Cash was £0.09m from £1.68m in H1 2025 while group cash headroom was £1.52m.
The Group has focussed on winning new business in the UK and Germany, alongside cost control and efficiency improvements. 


Hybridan Small Cap Feast: 25 November 2025

<ul>
<li>capAI 1.16p £2.91m (CPAI.L) The AI developer reports a strategic update at its AGM.</li>
<li>There is continued strong execution across its platform portfolio, which is entering a key inflection point, with multiple products transitioning from development into live user availability.</li>
<li>The sector focus is across preventative health, media platforms and the development and commercialisation of associated content. </li>
</ul>


capAI 1.16p £2.91m (CPAI.L) The AI developer reports a strategic update at its AGM.
There is continued strong execution across its platform portfolio, which is entering a key inflection point, with multiple products transitioning from development into live user availability.
The sector focus is across preventative health, media platforms and the development and commercialisation of associated content. 


<ul>
<li>Abingdon Health 8.25p £20.71m (ABDX.L) The developer, manufacturer and regulatory services provider for rapid diagnostic tests and medtech reports H1 to December 2025.</li>
<li>Reported revenue is 37% higher at £4.2m, with an EBITDA loss of £1.7m compared to an EBITDA loss of £1.9m due to continued investment in the overhead base to support future growth and contract execution.</li>
<li>The net cash is £3.7m against £1.9m last year and after a fund raising in October 2025 of £3.2m to accelerate US expansion and support execution of major contracts. </li>
</ul>


Abingdon Health 8.25p £20.71m (ABDX.L) The developer, manufacturer and regulatory services provider for rapid diagnostic tests and medtech reports H1 to December 2025.
Reported revenue is 37% higher at £4.2m, with an EBITDA loss of £1.7m compared to an EBITDA loss of £1.9m due to continued investment in the overhead base to support future growth and contract execution.
The net cash is £3.7m against £1.9m last year and after a fund raising in October 2025 of £3.2m to accelerate US expansion and support execution of major contracts. 


<ul>
<li>The exploration and development company announced that it has raised gross proceeds of £375,192 via an allotment to Kashif Afzal, a Director of the Company, of 31,266,000 new ordinary shares at an issue price of £0.012 per share, representing a premium of approximately 50% to the closing mid-market price at 8 Oct 2025.</li>
<li>The purchaser will receive one warrant for each New Ordinary Share exercisable at £0.02, where they are exercisable for a period of five years from the date of issue.</li>
<li>The company also sold 443k shares in Sterling Metals Corp for approximately a gross consideration of CAD980k. The Company will retain 400,000 shares in Sterling Metals.</li>
</ul>


The exploration and development company announced that it has raised gross proceeds of £375,192 via an allotment to Kashif Afzal, a Director of the Company, of 31,266,000 new ordinary shares at an issue price of £0.012 per share, representing a premium of approximately 50% to the closing mid-market price at 8 Oct 2025.
The purchaser will receive one warrant for each New Ordinary Share exercisable at £0.02, where they are exercisable for a period of five years from the date of issue.
The company also sold 443k shares in Sterling Metals Corp for approximately a gross consideration of CAD980k. The Company will retain 400,000 shares in Sterling Metals.


United Kingdom

Intercede is a cybersecurity software company specializing in digital identities, credential management, and secure mobility solutions. It provides a suite of products, including MyID, for organizations to create, issue, and manage trusted digital identities and replace insecure passwords with strong authentication. The company was founded in 1992 and is headquartered in Lutterworth, United Kingdom.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Intercede (IGP LN)

Hybridan Small Cap Feast: 20 May 2026

The owner and operator of Wildwood and dim t restaurants updates on trading for the first four and a half months to 17 May 2026 at its AGM. Revenue...

Hybridan

Hybridan Small Cap Feast: 25 November 2025

Revenue in H1 2026 decreased by 12.3% to £8.59m (H1 2025: £9.79m), while the gross profit decreased by 4.6% to £2.90m (H1 2025: £3.04m).

Hybridan

Hybridan Small Cap Feast: 21 April 2026

There is continued strong execution across its platform portfolio, which is entering a key inflection point, with multiple products transitioning...

Hybridan

Hybridan Small Cap Feast: 17 March 2026

Abingdon Health 8.25p £20.71m (ABDX.L) The developer, manufacturer and regulatory services provider for rapid diagnostic tests and medtech reports...

Hybridan

Hybridan Small Cap Feast: 09/10/2025

The purchaser will receive one warrant for each New Ordinary Share exercisable at £0.02, where they are exercisable for a period of five years from...

Hybridan

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)